BLOG POST
Rare disease outreach is most effective when it starts before diagnosis, using symptom-based point-of-care engagement to reach patients earlier and reduce missed awareness opportunities.
For rare disease brands, reaching patients has never exactly been simple. Patient populations are tiny, often scattered across the country and hard to identify. Awareness of rare diseases is low, not just among patients, but among healthcare professionals who may go their entire career without seeing a single case. Most traditional marketing models weren’t built for this reality.
On top of that, timing makes everything harder. Many rare disease journeys start years before a condition is ever named, long before diagnosis-based audience definition can do any real work. When marketing waits for a confirmed diagnosis, brands miss a long stretch of uncertainty where patients and providers are actively searching for answers.
If brands want to make an impact earlier, rare disease awareness must start before a diagnosis has been made. That means reaching people based on symptoms and early care-seeking behaviors, as well as showing up at moments when patients are open to receiving information. If patients are able to begin treatment at this earlier stage, this may improve their chances of having better health outcomes.
The hidden gap in rare disease awareness
Many rare disease marketing strategies are built around confirmed diagnoses. From a planning perspective, that makes sense. Diagnosis codes are familiar and measurable. But the reality for patients is much more complicated.
Patients with rare conditions often spend, on average, more than five years cycling through symptoms, appointments and misdiagnoses before reaching the right answer. Early symptoms are frequently nonspecific—fatigue, unexplained chronic pain, recurring infections, gastrointestinal issues—and easily attributed to more common conditions. During this journey, many patients will see six physicians or more, but even through a series of medical visits, specialist referrals and tests, they may not get clear answers.
For marketing teams, this creates a major gap. When awareness efforts focus only on diagnosed patients, they risk excluding patients who are actively seeking care but haven’t yet been diagnosed. These undiagnosed patients are often still trying to understand what they’re experiencing and how to describe it to providers.
The limits of diagnosis-based education
Traditional marketing strategies struggle to solve this problem: How do we reach patients who are searching for answers, but don’t yet have a diagnosis that makes them identifiable?
Of course, “expanding reach” is easier said than done. If marketing teams cast too wide of a net, they risk inefficiency. But if they narrow their focus too early, they can exclude those patients who might benefit from education.
The question then becomes: How can rare disease brands reach patients with relevant symptoms?
Meeting patients at the point of care
One answer lies at the point of care. Patients are already engaged, focused on their health and preparing to speak with a provider. It’s a moment of heightened relevance, and one that doesn’t rely on a confirmed diagnosis to be meaningful.
By meeting patients at the point of care, brands can align education with why patients are there in the first place, even if they don’t have a diagnosis.
Information delivered at the point of care can shape how patients think about their symptoms, what questions they ask and how confidently they engage with their providers in the exam room. Instead of passively consuming awareness messages, patients are empowered to participate in their care and advocate for themselves.
But showing up at the point of care is only part of the equation. How rare disease brands engage patients in that moment matters just as much. Symptom-first engagement doesn’t mean overwhelming patients with disease-state education or suggesting diagnoses before a clinician does. The goal is never to tell patients what they have, but rather to help them articulate what symptoms or issues they’re experiencing.
When done well, symptom-based relevance allows brands to expand reach while building and maintaining trust. Education can focus on helping patients recognize symptom patterns, prepare questions or understand when it may be appropriate to seek further evaluation, all without naming or implying a specific rare disease. This kind of support respects the uncertainty patients are already living with, rather than adding fear or urgency.
Using symptom patterns helps identify patients who are most likely to benefit from guidance, even if they don’t yet have a diagnosis. It captures the attention of people earlier in their journey, when awareness can still influence the path forward, while also keeping the message supportive and appropriate.
By engaging symptom-based audiences at the point of care, rare disease brands can:
- Reach patients early in their journey, before years of delay could make the course of treatment more complex
- Support more meaningful patient–provider conversations
- Increase the likelihood that concerning symptom patterns are recognized sooner
Rare disease awareness can’t wait for a diagnosis
Rare disease journeys don’t begin with a diagnosis. They begin with confusing symptoms, uncertainty and repeated attempts to find answers; that early window is when patients and providers are actively searching for clarity. By focusing on symptom-based relevance and engaging patients at the point of care, rare disease brands can show up earlier with education that supports better questions, stronger patient–provider conversations and more timely recognition of concerning patterns. Starting awareness before diagnosis isn’t about broader reach, it’s about reaching the right patients sooner, with precision, empathy and purpose.
Rare disease awareness doesn’t have to wait for a diagnosis. Request a demo today to learn how engagement at the point of care can help your brand reach patients sooner and support more meaningful patient–provider conversations.
